CLINICAL TRIALS PROFILE FOR DOLASETRON MESYLATE
✉ Email this page to a colleague
All Clinical Trials for dolasetron mesylate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003817 ↗ | Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy | Completed | National Cancer Institute (NCI) | Phase 2 | 1999-10-01 | RATIONALE: Pressure or nerve stimulation applied to an acupuncture point on the inside of the wrist may help control nausea and vomiting during chemotherapy. PURPOSE: Randomized phase II trial to study the effectiveness of acupressure and acustimulation wrist bands in treating nausea and vomiting in patients undergoing chemotherapy for cancer. |
| NCT00003817 ↗ | Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy | Completed | Gary Morrow | Phase 2 | 1999-10-01 | RATIONALE: Pressure or nerve stimulation applied to an acupuncture point on the inside of the wrist may help control nausea and vomiting during chemotherapy. PURPOSE: Randomized phase II trial to study the effectiveness of acupressure and acustimulation wrist bands in treating nausea and vomiting in patients undergoing chemotherapy for cancer. |
| NCT00020657 ↗ | Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer | Completed | National Cancer Institute (NCI) | Phase 3 | 2001-07-01 | RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer. |
| NCT00020657 ↗ | Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer | Completed | Gary Morrow | Phase 3 | 2001-07-01 | RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer. |
| NCT02550119 ↗ | Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy | Terminated | National Cancer Institute (NCI) | N/A | 2006-04-19 | This randomized pilot clinical trial dolasetron mesylate and dexamethasone with or without aprepitant in preventing nausea and vomiting in patients undergoing oxaliplatin-containing chemotherapy for gastrointestinal malignancy. Antiemetic drugs may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. It is not yet known whether giving aprepitant together with dolasetron mesylate and dexamethasone is more effective than dolasetron mesylate and dexamethasone alone in preventing nausea and vomiting. |
| NCT02550119 ↗ | Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy | Terminated | University of Southern California | N/A | 2006-04-19 | This randomized pilot clinical trial dolasetron mesylate and dexamethasone with or without aprepitant in preventing nausea and vomiting in patients undergoing oxaliplatin-containing chemotherapy for gastrointestinal malignancy. Antiemetic drugs may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. It is not yet known whether giving aprepitant together with dolasetron mesylate and dexamethasone is more effective than dolasetron mesylate and dexamethasone alone in preventing nausea and vomiting. |
| NCT02625181 ↗ | Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis | Completed | University of Washington | N/A | 2016-07-01 | The purpose of this study is to determine how automated recommendations are best presented to optimize the adherence to guidelines on prophylaxis for nausea and vomiting after surgery. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for dolasetron mesylate
Condition Name
| Condition Name for dolasetron mesylate | |
| Intervention | Trials |
| Nausea and Vomiting | 3 |
| Unspecified Adult Solid Tumor, Protocol Specific | 2 |
| Malignant Digestive System Neoplasm | 1 |
| Postoperative Nausea and Vomiting | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for dolasetron mesylate
Trials by Country
Clinical Trial Progress for dolasetron mesylate
Clinical Trial Phase
Clinical Trial Sponsors for dolasetron mesylate
Sponsor Name
